DAX24.490 +0,6%Est505.791 -0,1%MSCI World4.343 -0,1%Top 10 Crypto11,63 -0,5%Nas23.242 -0,8%Bitcoin74.471 -1,1%Euro1,1749 ±0,0%Öl60,85 -1,7%Gold4.312 -0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 DroneShield A2DMAA Bayer BAY001 Deutsche Telekom 555750 Novo Nordisk A3EU6F Lufthansa 823212 Allianz 840400 Tesla A1CX3T Infineon 623100 Amazon 906866 Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 BYD A0M4W9 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet letzten Handelstag 2025 freundlich -- Rheinmetall, RENK, HENSOLDT & TKMS: Putin wirft Ukraine Terror vor -- TUI, Palantir, Meta im Fokus
Top News
Morgan Stanley Investment-Ausblick: So könnten US-Aktien, Gold, Öl & Co. 2026 performen Morgan Stanley Investment-Ausblick: So könnten US-Aktien, Gold, Öl & Co. 2026 performen
ETF-Depot eröffnen: Was Anleger vor dem ersten Kauf wissen sollten ETF-Depot eröffnen: Was Anleger vor dem ersten Kauf wissen sollten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

INNATE PHARMA SA Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
1,58 EUR +0,04 EUR +2,60 %
BMN
1,61 EUR +0,06 EUR +4,15 %
PAR
INNATE PHARMA SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.142,32 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0LCUJ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0010331421

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIPHYF

INNATE PHARMA SA Aktien News

DatumMeistgelesen
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Businesswire Innate Pharma Announces Transformative Strategy to Accelerate Growth
BusinesswireInnate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Wer­bungINNATE PHARMA SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
BusinesswireInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
BusinesswireInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
BusinesswireInnate Pharma Releases Its 2025 Financial Calendar
BusinesswireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
BusinesswireInnate Pharma Reports Third Quarter 2024 Business Update and Financial Results
BusinesswireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
BusinesswireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conferences
BusinesswireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
BusinesswireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
BusinesswireInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
BusinesswireInnate Pharma Reports First Half 2024 Business Update and Financial Results
BusinesswireInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
BusinesswireInnate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
BusinesswireInnate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conference
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of July 10, 2024
BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024
BusinesswireInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
BusinesswireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conferences
BusinesswireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
BusinesswireOutcome of Innate Pharma’s 2024 Annual General Meeting
BusinesswireInnate Pharma: Clarification Regarding SAR443579 Designation
BusinesswireInnate Pharma Highlights Abstracts Selected for EHA 2024 Congress
BusinesswireInnate Pharma Reports First Quarter 2024 Business Update and Financial Results
BusinesswireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
BusinesswireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
BusinesswireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
BusinesswireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conference
BusinesswireInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
BusinesswireInnate Pharma Reports Full Year 2023 Financial Results and Business Update
BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conference
BusinesswireInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
BusinesswireInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

INNATE PHARMA SA News

INNATE PHARMA SA News: auf dieser Seite finden Sie alle INNATE PHARMA SA News und Nachrichten zur INNATE PHARMA SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch INNATE PHARMA SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um INNATE PHARMA SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.